A carregar...
Ruxolitinib for the treatment of myelofibrosis: its clinical potential
Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function. By inhibiting JAK1 and JAK2, ruxolitinib modu...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3295626/ https://ncbi.nlm.nih.gov/pubmed/22399854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S23277 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|